Format

Send to

Choose Destination
Nat Commun. 2017 Oct 10;8(1):845. doi: 10.1038/s41467-017-00900-1.

The gut microbiome in atherosclerotic cardiovascular disease.

Jie Z1,2,3, Xia H1,2, Zhong SL4,5, Feng Q1,2,6,7,8, Li S1, Liang S1,2, Zhong H1,2,3,7, Liu Z1,9, Gao Y1,2, Zhao H1, Zhang D1, Su Z1, Fang Z1, Lan Z1, Li J1,2,3,10, Xiao L1,2,6, Li J1, Li R11, Li X1,2, Li F1,2,9, Ren H1, Huang Y1, Peng Y1,12, Li G1, Wen B1,2, Dong B1, Chen JY4, Geng QS4, Zhang ZW4, Yang H1,2,13, Wang J1,2,13, Wang J1,14,15, Zhang X16, Madsen L1,2,7,17, Brix S18, Ning G19, Xu X1,2, Liu X1,2, Hou Y1,2, Jia H20,21,22,23, He K24, Kristiansen K25,26,27.

Author information

1
BGI-Shenzhen, Shenzhen, 518083, China.
2
China National Genebank, Shenzhen, 518120, China.
3
Shenzhen Key Laboratory of Human Commensal Microorganisms and Health Research, BGI-Shenzhen, Shenzhen, 518083, China.
4
Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangzhou, 510080, China.
5
Medical Research Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
6
Shenzhen Engineering Laboratory of Detection and Intervention of Human Intestinal Microbiome, Shenzhen, 518083, China.
7
Department of Biology, Laboratory of Genomics and Molecular Biomedicine, University of Copenhagen, Universitetsparken 13, 2100, Copenhagen, Denmark.
8
Department of Human Microbiome, School of Stomatology, Shandong University, Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, 250012, China.
9
BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, 518083, China.
10
School of Bioscience and Biotechnology, South China University of Technology, Guangzhou, 510006, China.
11
Beijing Key Laboratory for Precision Medicine of Chronic Heart Failure, Chinese PLA General Hospital, Beijing, 100853, China.
12
Center for Genome Sciences & Systems Biology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
13
James D. Watson Institute of Genome Sciences, Hangzhou, 310000, China.
14
Macau University of Science and Technology, Macau, 999078, China.
15
iCarbonX, Shenzhen, 518053, China.
16
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
17
National Institute of Nutrition and Seafood Research, (NIFES), Postboks 2029, Nordnes, N-5817, Bergen, Norway.
18
Department of Biotechnology and Biomedicine, Technical University of Denmark (DTU), 2800, Kongens Lyngby, Denmark.
19
Department of Endocrinology and Metabolism, State Key Laboratory of Medical Genomes, National Clinical Research Center for Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
20
BGI-Shenzhen, Shenzhen, 518083, China. jiahuijue@genomics.cn.
21
China National Genebank, Shenzhen, 518120, China. jiahuijue@genomics.cn.
22
Shenzhen Key Laboratory of Human Commensal Microorganisms and Health Research, BGI-Shenzhen, Shenzhen, 518083, China. jiahuijue@genomics.cn.
23
Macau University of Science and Technology, Macau, 999078, China. jiahuijue@genomics.cn.
24
Beijing Key Laboratory for Precision Medicine of Chronic Heart Failure, Chinese PLA General Hospital, Beijing, 100853, China. hekl301@aliyun.com.
25
BGI-Shenzhen, Shenzhen, 518083, China. kk@bio.ku.dk.
26
China National Genebank, Shenzhen, 518120, China. kk@bio.ku.dk.
27
Department of Biology, Laboratory of Genomics and Molecular Biomedicine, University of Copenhagen, Universitetsparken 13, 2100, Copenhagen, Denmark. kk@bio.ku.dk.

Abstract

The gut microbiota has been linked to cardiovascular diseases. However, the composition and functional capacity of the gut microbiome in relation to cardiovascular diseases have not been systematically examined. Here, we perform a metagenome-wide association study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 healthy controls. The ACVD gut microbiome deviates from the healthy status by increased abundance of Enterobacteriaceae and Streptococcus spp. and, functionally, in the potential for metabolism or transport of several molecules important for cardiovascular health. Although drug treatment represents a confounding factor, ACVD status, and not current drug use, is the major distinguishing feature in this cohort. We identify common themes by comparison with gut microbiome data associated with other cardiometabolic diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis. Our data represent a comprehensive resource for further investigations on the role of the gut microbiome in promoting or preventing ACVD as well as other related diseases.The gut microbiota may play a role in cardiovascular diseases. Here, the authors perform a metagenome-wide association study on stools from individuals with atherosclerotic cardiovascular disease and healthy controls, identifying microbial strains and functions associated with the disease.

PMID:
29018189
PMCID:
PMC5635030
DOI:
10.1038/s41467-017-00900-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center